P 1037

Drug Profile

P 1037

Alternative Names: GS-5737; P-1037; VX 371

Latest Information Update: 31 Aug 2016

Price : $50

At a glance

  • Originator Parion Sciences
  • Developer Parion Sciences; Vertex Pharmaceuticals
  • Class Antibronchitics
  • Mechanism of Action Epithelial sodium channel-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis; Primary ciliary dyskinesia

Most Recent Events

  • 01 Aug 2016 Phase-II clinical trials in Primary ciliary dyskinesia (In adolescents, In adults) in USA (unspecified route) (NCT02871778)
  • 01 Feb 2016 Vertex Pharmaceuticals and Parion completes a phase II trial in Cystic fibrosis (In adolescents, In adults, In the elderly) in USA (NCT02343445)
  • 01 Feb 2016 Phase-II clinical trials in Cystic fibrosis (In adolescents, In adults) in United Kingdom (Inhalation) (NCT02709109)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top